Oral Oncology
Volume 40, Issue 7 , Pages 713-719 , August 2004

Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells

  • Koji Harada

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-88-633-7354; fax: +81-88-633-7462
    • ,
  • Shin-ichi Kawaguchi

      Affiliations

    • Department of Oral and Maxillofacial Radiology, University of Tokushima, School of Dentistry, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Supriatno

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Tomitaro Onoue

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Hideo Yoshida

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan
    • ,
  • Mitsunobu Sato

      Affiliations

    • Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan

Received 19 December 2003 ,Accepted 7 January 2004.

References 

  1. Nakajima Y, Miyamoto T, Tanabe M, Watanabe I, Terasima T. Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays. Cancer Res. 1979;39(9):3763–3767
  2. Smalley SR, Kimler BF, Evans RG. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys. 1991;20(2):207–211
  3. Balart J, Capella G, de los Inocentes RM, de Andres J, Ares C, Craven-Bartle J, et al.  Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2. Pancreatology. 2002;2(1):40–45
  4. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548–557
  5. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, et al.  Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998;13(4):693–698
  6. Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, et al.  Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs. 1998;9(9):817–823
  7. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34(11):1715–1720
  8. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al.  Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85(7):939–943
  9. Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, et al.  Phase I and pharmacokinetic study of once daily oral administration of S-1in patients with advanced cancer. Clin Cancer Res. 2002;8(7):2116–2122
  10. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho. 2001;28(10):1381–1390 Japanese, abstract in English
  11. Supriatno , Harada K, Hoque MO, Bando T, Yoshida H, Sato M. Overexpression of p27Kip1 induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol. 2002;38:730–736
  12. Shirasuna K, Sato M, Miyazaki T. A neoplastic epithelial duct cell line established from an irradiated human salivary gland. Cancer (Phila.). 1981;48:745–752
  13. Shirasuna K, Kurokawa R, Sato M, Morioka S, Miyazaki T. Isolation and characterization of different clones including myoepithelial-like variants from a clonal neoplastic epithelial duct cell line of human salivary gland origin. Cancer Res. 1986;46:1418–1426
  14. In:  Johnson RR editors. Elementary statistics. Massachusetts: Duxbury Press; 1980;
  15. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5(1):85–91
  16. Berry RJ. Effects of some metabolic inhibitors on X-ray dose-response curves for the survival of mammalian cells in vitro, and on early recovery between fractionated X-ray doses. Br J Radiol. 1966;39(462):458–463
  17. Lo TC, Wiley AL, Ansfield FJ, Brandenburg JH, Davis HL, Gollin FF, et al.  Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am J Roentgenol. 1976;126(2):229–235
  18. Matsubara S. Fundamental remarks on combination radiotherapy with anti-neoplastic agents. Jpn J Cancer Clin. 1999;45(4):271–273 Japanese, abstract in English
  19. Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 1984;2(11):1289–1304
  20. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53(17):4004–4009

PII: S1368-8375(04)00024-7

doi: 10.1016/j.oraloncology.2004.01.013

Oral Oncology
Volume 40, Issue 7 , Pages 713-719 , August 2004

Article Tools

* Image Usage & Resolution